In a nutshell This study assessed the safety and impact on the growth of nilotinib (Tasigna) in children with chronic myeloid leukemia (CML). The data indicated reduced growth rates with nilotinib treatment in children with CML. Some background Chronic myeloid leukemia (CML) is rare in children. However, it affects younger patients more...
Read More
In a nutshell This study compared the safety and effectiveness between pyrotinib (SHR-1258) and trastuzumab emtansine (T-DM1; Kadcyla) in patients with HER2+ metastatic breast cancer (BC) after previous treatment with trastuzumab (Herceptin) and chemotherapy. The data showed that pyrotinib may be more effective than T-DM1 for these patients. Some...
Read More
In a nutshell This study compared the safety and effectiveness of pyrotinib (SHR-1258) plus capecitabine (Xeloda) versus lapatinib (Tyverb) plus capecitabine in patients with metastatic human epidermal growth factor (HER2)-positive breast cancer (BC) after previous treatment with trastuzumab (Herceptin) and chemotherapy. The data...
Read More
In a nutshell This trial is looking to examine the effectiveness of carboplatin (Paraplatin), paclitaxel (Taxol), and ramucirumab (Cyramza) in the treatment of advanced non-squamous non-small cell lung cancer (NSCLC) that is progressive after maintenance therapy. The main outcome that is to be measured is the response of the...
Read More
In a nutshell This article reviewed the skin side effects caused by anti-PD-1 biological therapy. Some background Anti-PD-1 is a type of biological therapy that has significantly improved treatment results for patients with certain types of cancer. It works by blocking PD-1, a molecule that cancer cells use to switch off the immune...
Read MoreIn a nutshell This study aimed to investigate the effect of stopping trastuzumab treatment in patients with HER2-positive metastatic breast cancer with radiological complete remission. This study concluded that trastuzumab may be safely stopped in selected patients with radiological complete...
Read MoreIn a nutshell This phase 2 trial will investigate the effect of vopratelimab (JTX-2011) and ipilimumab (Yervoy) in non-small cell lung cancer (NSCLC). The main outcome will be the overall response (OR). This trial is recruiting at multiple locations in the US. The details Non-small cell lung cancer (NSCLC) is the most...
Read MoreIn a nutshell This study is searching for patients with chronic myeloid leukemia (CML) to try a new drug ruxolitinib (NSC-752295) with BCR-ABL Tyrosine Kinase Inhibitors. The main outcome that will be measured is the rate of significant reduction of the BCR-ABL marker. This trial is recruiting across the United States. The details BCR-ABL is a protein...
Read MoreIn a nutshell This study summarised the side effects of ibrutinib (Imbruvica) and how to manage them. Some background Ibrutinib is an FDA approved drug used to treat lymphoma and leukemia. It works on the immune cells in the body which may lead to many side effects. These include diarrhea, upper respiratory infections, bleeding, tiredness,...
Read MoreIn a nutshell This phase 2 trial will investigate the effectiveness of genetically-engineered cell treatment (GECT) in advanced cancer. The main outcome will be the response to treatment. This trial is recruiting at the National Cancer Institute, Maryland, US. The details There are limited treatment options for advanced cancer. One...
Read MoreIn a nutshell This phase 2 trial will investigate the safety and effectiveness of different treatment combinations containing durvalumab (Imfinzi) in non-small cell lung cancer (NSCLC). The main outcome will be the objective response rate (ORR). The details Non-small cell lung cancer (NSCLC) is a common form of lung cancer. It is often diagnosed at...
Read MoreIn a nutshell This trial is examining the effectiveness of circulating cell-free tumor DNA (cCFTD) as a predictive factor for the treatment of advanced colorectal cancer with regorafenib (Stivarga) or TAS-102. The main outcome to be measured will be to evaluate the ability of early change of cCFTD after the start of the treatment. This trial will be...
Read More
